NCT02264171已完成1 期
An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Cmax (maximum measured concentration of Tamsulosin HCl in plasma)
研究概览
简要总结
Study to investigate the effect of CYP3A4 inhibition by ketoconazole on the single oral dose pharmacokinetics of tamsulosin and to investigate the effect on safety and tolerability
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •All participants in the study will be
- •Healthy males
- •Ranging from 21 to 50 years of age
- •Body mass index (BMI) within 18.5 to 29.9 kg/m2 (BMI calculation: weight in kilograms divided by the square of height in meters)
- •In accordance with Good Clinical Practice (GCP) and the local legislation all volunteers will have given their written informed consent prior to admission to the study
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders, clinically relevant electrolyte disturbances
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or clinically relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
- •Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study
- •Participation in another trial with an investigational drug (within two months prior to administration or during the trial)
- •Smoker (> 10 cigarettes or > 3 cigars of > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Blood donation (> 100 mL within four weeks prior to administration or during the trial)
- •Any laboratory value outside the reference range if indicative of underlying disease or poor health
- •Excessive physical activities within the last week before the trial or during the trial
- •Hypersensitivity to treatment medication and/or related drugs of these classes
- •Non extensive metabolizer (EM) for CYP2D6
研究组 & 干预措施
Ketoconazole + Tamsulosin HCl
Experimental
Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
干预措施: Tamsulosin HCl (Drug)
Ketoconazole + Tamsulosin HCl
Experimental
Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
干预措施: Ketoconazole (Drug)
Tamsulosin HCl
Active Comparator
Tamsulosin HCl given at day 1
干预措施: Tamsulosin HCl (Drug)
结局指标
主要结局
Cmax (maximum measured concentration of Tamsulosin HCl in plasma)
时间窗: up to 48 hours after dosing
AUC0-∞ (Area under the concentration-time curve of Tamsulosin HCl in plasma over the time interval from 0 extrapolated to infinity)
时间窗: up to 48 hours after dosing
次要结局
- Ratio of the Cmax value of the Test treatment to the Cmax value of the Reference treatment after single dose (RCmax,T/R)(up to 48 hours after dosing)
- AUC0-tz (area under the concentration-time curve of Tamsulosin HCl in plasma over the time interval from 0 to the last quantifiable data point)(up to 48 hours after dosing)
- CL/F (apparent clearance of the analyte in the plasma after extravascular administration)(up to 48 hours after dosing)
- λz (terminal rate constant of Tamsulosin HCl in plasma)(up to 48 hours after dosing)
- Vz/F (apparent volume of distribution of Tamsulosin HCl during the terminal phase λz following an extravascular dose)(up to 48 hours after dosing)
- Number of subjects with adverse events(up to 21 days after last Tamsulosin administration)
- tmax (time from dosing to the maximum concentration of Tamsulosin HCl in plasma)(up to 48 hours after dosing)
- MRTpo (mean residence time Tamsulosin HCl in the body after oral administration)(up to 48 hours after dosing)
- Assessment of tolerability by investigator on a 4-point scale(within 21 days after last Tamsulosin administration)
- t1/2 (terminal half-life of Tamsulosin HCl in plasma)(up to 48 hours after dosing)
- Ratio of the Test treatment versus the Reference treatment from zero to infinity, expressed as ratio of AUC values after single dose (RAUC0-∞,T/R)(up to 48 hours after dosing)
研究者
相似试验
已完成
1 期
To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of AvanafilErectile DysfunctionNCT00770042VIVUS LLC44
已完成
1 期
GSK962040 Drug-drug Interaction Study With KetoconazoleGastroparesisNCT01039974GlaxoSmithKline6
已完成
1 期
Drug-Drug Interaction Study of Itraconazole With GST-HG171/Ritonavir in Healthy ParticipantsHealthy ParticipantNCT06087055Fujian Akeylink Biotechnology Co., Ltd.12
已完成
1 期
Drug-Drug Interaction Study Between Colchicine and KetoconazolePharmacokineticsNCT00983216Mutual Pharmaceutical Company, Inc.24
已完成
1 期
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy ParticipantsHealthy ParticipantsNCT03821493Pfizer12